- Jun 4, 2017
- 0 Comment
- 301 Views
The drug, larotrectinib, directly targets an acquired rather than inherited genetic defect called TRK fusions. In such patients, TRK genes abnormally attach to other genes, triggering accelerated cancer cell growth, according to Reuters.
If approved, the oral therapy would mark a major step